Explore a selection of our essential drug information below, or:
Identification
- Summary
Etilefrine is an adrenergic agonist primarily of α1 and β1 receptors used as an anti-hypotensive.
- Generic Name
- Etilefrine
- DrugBank Accession Number
- DB08985
- Background
Etilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors. It has been used as a vasoconstrictor agent.
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
Structure for Etilefrine (DB08985)
- Weight
- Average: 181.2316
Monoisotopic: 181.110278729 - Chemical Formula
- C10H15NO2
- Synonyms
- Etilefrina
- Etilefrine
- Etilefrinum
- External IDs
- S 40032
- S 40032-7
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Orthostatic hypotension •••••••••••• •••••••••• ••••••••• •••••••• • •••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The therapeutic efficacy of Etilefrine can be decreased when used in combination with Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Etilefrine. Acemetacin The risk or severity of hypertension can be increased when Etilefrine is combined with Acemetacin. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Etilefrine. Aclidinium The risk or severity of Tachycardia can be increased when Aclidinium is combined with Etilefrine. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Etilefrine hydrochloride ZBI6Q5FH3S 943-17-9 KTNROWWHOBZQGK-UHFFFAOYSA-N - International/Other Brands
- Apocretin / Circupon / Effontil / Effortil / Effortilvet / Eti-Puren / Kertasin / Phetanol / Phetasin / Tonus-Forte / Updormin
Categories
- ATC Codes
- C01CA51 — Etilefrine, combinations
- C01CA — Adrenergic and dopaminergic agents
- C01C — CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
- C01 — CARDIAC THERAPY
- C — CARDIOVASCULAR SYSTEM
- Drug Categories
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic alpha-Agonists
- Adrenergic and Dopaminergic Agents
- Adrenergic beta-1 Receptor Agonists
- Adrenergic beta-Agonists
- Agents producing tachycardia
- Agents that produce hypertension
- Alcohols
- Amines
- Amino Alcohols
- Autonomic Agents
- Cardiac Stimulants Excl. Cardiac Glycosides
- Cardiac Therapy
- Cardiotonic Agents
- Cardiovascular Agents
- Compounds used in a research, industrial, or household setting
- Ethanolamines
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Protective Agents
- Sympathomimetics
- Vasoconstrictor Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 1-hydroxy-4-unsubstituted benzenoids. These are phenols that are unsubstituted at the 4-position.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenols
- Sub Class
- 1-hydroxy-4-unsubstituted benzenoids
- Direct Parent
- 1-hydroxy-4-unsubstituted benzenoids
- Alternative Parents
- Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- 1,2-aminoalcohol / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Alcohol / Amine / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Hydrocarbon derivative / Monocyclic benzene moiety
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- ZB6F8MY53V
- CAS number
- 709-55-7
- InChI Key
- SQVIAVUSQAWMKL-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3
- IUPAC Name
- 3-[2-(ethylamino)-1-hydroxyethyl]phenol
- SMILES
- CCNCC(O)C1=CC=CC(O)=C1
References
- Synthesis Reference
British Patent 1,358,973.
- General References
- Not Available
- External Links
- KEGG Drug
- D07931
- PubChem Compound
- 3306
- PubChem Substance
- 310264946
- ChemSpider
- 3190
- BindingDB
- 97154
- 4169
- ChEBI
- 91518
- ChEMBL
- CHEMBL86882
- Wikipedia
- Etilefrine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Recruiting Treatment Blood Pressures / Intra-operative Hypotension / Postoperative Complications 1 somestatus stop reason just information to hide 2 Completed Treatment Hepatic Ascites 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Oral 0.750 g Tablet Oral 5.000 mg Solution Oral 5 mg/mL Capsule, extended release 25 MG Injection, solution Intramuscular; Subcutaneous 10 MG/1ML Injection, solution Intramuscular; Subcutaneous 15 mg/ml Solution Oral 7.5 mg/mL Solution / drops Oral Solution / drops Oral 7.5 MG/ML Tablet Oral Tablet Oral 5 mg/1 Injection, solution Intramuscular; Intravenous; Subcutaneous 10 mg Solution Oral 7.5 mg Solution Intramuscular; Intravenous; Subcutaneous 10 mg Tablet, coated Oral 5 mg Tablet Oral 5 mg Tablet, sugar coated Oral 5 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 208-209 British Patent 1,358,973. - Predicted Properties
Property Value Source Water Solubility 13.8 mg/mL ALOGPS logP 0.01 ALOGPS logP 0.23 Chemaxon logS -1.1 ALOGPS pKa (Strongest Acidic) 9.1 Chemaxon pKa (Strongest Basic) 9.73 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 52.49 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 52 m3·mol-1 Chemaxon Polarizability 20.33 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 136.75725 predictedDeepCCS 1.0 (2019) [M+H]+ 140.43416 predictedDeepCCS 1.0 (2019) [M+Na]+ 149.73622 predictedDeepCCS 1.0 (2019)
Drug created at June 10, 2014 17:55 / Updated at June 02, 2021 20:03